Dare Bioscience Inc (DARE)

[Viewmont]

Dare Bioscience, Inc. To Present At The 31st Annual ROTH Conference.

GlobeNewswire - Mon Mar 18, 7:29AM CDT
Dare Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced that Sabrina Johnson, President and Chief Executive Officer, will present at the 31st Annual ROTH Conference on Tuesdsay, March 19, 2019 starting at 9:30 a.m. Pacific Time in Orange County, CA. Ms. Johnson will present a Dare overview and provide an update on the Company's new late-stage bacterial vaginosis program, DARE-BV1, a proprietary solution-to-gel formulation containing clindamycin, an antibiotic used to treat bacterial infections, as well as Dare's mid-stage programs: Ovaprene(R), a potential first-in-class hormone-free contraceptive solution; and Sildenafil Cream, 3.6%, a novel vaginally delivered formulation of sildenafil, the active ingredient in Viagra(R), for the potential treatment of female sexual arousal disorder (FSAD). Ms. Johnson will also review Dare's earlier stage programs, including DARE-HRT1, a potential first combination vaginal ring that would deliver both natural estradiol and natural progesterone together over 28 days to treat vasomotor symptoms (VMS) associated with menopause as part of a hormone replacement therapy regimen.